eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

Molnlycke Health Care

Two Omega Drive, Irlam, Manchester, M44 5BJ , UK
Telephone: +44 (0)161 777 2600
Fax: +44 (0)161 777 2601
WWW: http://www.molnlycke.com
Medical Information Direct Line: +44 (0)161 777 2628
Medical Information e-mail: ukmedical.information@molnlycke.com
Customer Care direct line: +44 (0)161 777 2600
Medical Information Fax: +44 (0)161 621 2045

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 26/09/2006
SPC Hibisol


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Hibisol 0.5% w/v Cutaneous Solution.


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Chlorhexidine gluconate solution 2.5% w/v (incorporated as Chlorhexidine gluconate solution 20%).

For excipients, see 6.1.


Go to top of the page
3. PHARMACEUTICAL FORM

Cutaneous solution. Clear, colourless, non-viscous solution having an odour of isopropyl alcohol.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

For the disinfection of clean and intact skin. For pre-operative surgical hand disinfection, hand disinfection on the ward prior to aseptic procedures or after handling contaminated materials. For disinfection of the patients' skin prior to surgery or other invasive procedures.


Go to top of the page
4.2 Posology and method of administration

Route of administration: For external use only

Adults

Pre-operative surgical hand disinfection - Dispense 5ml of Hibisol and spread thoroughly over both hands and forearms, rubbing vigorously. When dry apply a further 5ml and repeat the procedure.

Antiseptic hand disinfection on the ward - Dispense 3ml of Hibisol and spread thoroughly over the hands and wrists rubbing vigorously until dry.

Disinfection of patients' skin - Prior to surgery apply Hibisol to a sterile swab and rub vigorously over the operation site for a minimum of 2 minutes. Hibisol is also used for preparation of the skin prior to invasive procedures such as venepuncture.

Elderly and children

There are no special dosing regimes for children and the elderly.


Go to top of the page
4.3 Contraindications

Hibisol is contraindicated for persons who have previously shown a hypersensitivity reaction to chlorhexidine. However, such reactions are extremely rare.


Go to top of the page
4.4 Special warnings and precautions for use

For external use only. Avoid contact with the brain, meninges or middle ear. Not for injection. Do not use in body cavities.

The solution is irritant to eyes and mucous membranes. Keep out of eyes. If chlorhexidine solutions come into contact with the eyes, wash out promptly and thoroughly with water.

Flammable – this preparation contains alcohol: when use is to be followed by diathermy do not allow pooling of the fluid to occur, and ensure that the skin and surrounding drapes are dry.

Prolonged skin contact with alcoholic solutions should be avoided, allow to dry before proceeding.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

See section 6.2.


Go to top of the page
4.6 Pregnancy and lactation

No untoward effects are known.


Go to top of the page
4.7 Effects on ability to drive and use machines

None known.


Go to top of the page
4.8 Undesirable effects

Irritative skin reactions can occasionally occur. Generalised allergic reactions have also been reported but are extremely rare.


Go to top of the page
4.9 Overdose

Overdosage is very unlikely.

Accidental ingestion: chlorhexidine taken orally is poorly absorbed. Treat with gastric lavage using milk, raw egg, gelatin or mild soap avoiding pulmonary aspiration. Do not use apomorphine. Assist respiration if necessary and keep the patient warm. Intravenous laevulose can accelerate alcohol metabolism. In severe cases, haemodialysis or peritoneal dialysis may be necessary.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Chlorhexidine is effective against a wide range of gram-negative and gram-positive vegetative bacteria, yeasts, dermatophyte fungi and lipophilic viruses. It is inactive against bacterial spores except at elevated temperatures.


Go to top of the page
5.2 Pharmacokinetic properties

Because of its cationic nature, chlorhexidine binds strongly to skin, mucosa and other tissues and is thus very poorly absorbed. No detectable blood levels have been found in man following oral use and percutaneous absorption, if it occurs at all, is insignificant.


Go to top of the page
5.3 Preclinical safety data

Chlorhexidine is a drug on which extensive clinical experience has been obtained. All relevant information for the prescriber is provided elsewhere in the Summary of Product Characteristics.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Cyclomethicone 5; isopropyl isostearate; isopropyl alcohol; purified water.


Go to top of the page
6.2 Incompatibilities

Chlorhexidine is incompatible with soap and other anionic agents. Hypochlorite bleaches may cause brown stains to develop in fabrics, which have previously been in contact with preparations containing chlorhexidine.


Go to top of the page
6.3 Shelf life

36 months unopened.


Go to top of the page
6.4 Special precautions for storage

Do not store above 25oC (flammable).


Go to top of the page
6.5 Nature and contents of container

White HDPE bottle (500ml).


Go to top of the page
6.6 Special precautions for disposal and other handling

None.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Regent Medical Overseas Limited, Two Omega Drive, River Bend Technology Centre, Irlam, Manchester, M44 5BJ, United Kingdom.


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 21855/0003.


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

30th December 2004.


Go to top of the page
10. DATE OF REVISION OF THE TEXT

February 2006.



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/18857/SPC/


Active Ingredients/Generics

 
   chlorhexidine gluconate